drugset / Trial / NCT03464058

Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

NCT03464058

Phase 1 Completed 28 enrolled Boston Pharmaceuticals
RandomizedCrossoverTriple-blindBasic science

Summary

Part 1 of the study will be conducted to provide additional information on the safety and tolerability of single doses of BOS172767 in healthy participants, to evaluate the pharmacokinetic (PK) profiles (including relative bioavailability) of BOS172767 following oral administration of 3 prototype formulations in healthy participants compared to an immediate release capsule formulation (reference), and also to determine the relative bioavailability of a selected BOS172767 prototype formulation in the fed and fasted states. Part 2 of the study will be conducted to provide additional information on the safety and tolerability of escalating single doses of the selected formulation of BOS172767 in healthy participants, to evaluate the PK profile following increased single doses of the selected formulation of BOS172767 following administration in healthy participants, and also to evaluate the dose linearity of the selected prototype. Part 3 of the study will be conducted to provide additional information on the safety, tolerability, and PK of the selected formulation of BOS172767 following multiple ascending doses (MADs) over 14 days of dosing in healthy participants.

Timeline

Start
2018-03-21
Primary completion
2018-10-09
Completion
2018-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BOS172767 Unknown 200 mg
Subject BOS172767 Unknown 400 mg
Subject BOS172767 Unknown 600 mg
Subject BOS172767 Unknown 800 mg
Subject Rabeprazole Small molecule Oral

Indications

No indication recorded.